Bicycle Therapeutics, a Phase 1 biotech developing novel oncology medicines based on bicyclic peptides, raised $61 million by offering 4.3 million ADSs at $14, the low end of the range of $14 to $16. Insiders had intended to purchase up to $25 million of the IPO. The UK-based company plans to list on the Nasdaq under the symbol BCYC. Goldman Sachs, Jefferies and Piper Jaffray acted as joint book-running managers on the deal.
The article Cancer biotech Bicycle Therapeutics prices US IPO at $14, the low end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This StoryBCYC
Latest IPOs Videos
- US IPO Week Ahead: Rocket Companies shoots for the moon in an 8 IPO week
- Customer support services provider IBEX prices IPO at $19, below the range
- E-commerce platform BigCommerce raises range to $21 to $23, adds insider selling ahead of $198 million IPO
- Apollo Global's Rackspace Technology prices IPO at $21, the low end of the range